Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

Overview of attention for article published in Infection and Drug Resistance, December 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 2 X users

f1000: 1 research highlight platform

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 55 Mendeley

Summary X Research highlights Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 4,899 followers.

@DCharabaty @Khanna_S @MondayNightIBD @apc_md @AnnieC_ID_MD @IBDMD @DrJessicaA @fudmanMD @RShivashankarMD @HorstIBDDoc @GKochharMD @Waseem_AhmedMD @Dana_Lukin @JeanDonet @joshsteinbergMD @JPAchkarMD Since the pandemic no #FMT was performed With regards to

Reply Repost Favourite

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile. https://t.co/IU2PHn6iPo #cdiff

Reply Repost Favourite

Bezlotoxumab for the prevention of Clostridium difficile inf | IDR - Dove Medical Press https://t.co/C2i0lDnXS3 #cdiff

Reply Repost Favourite